Medigene AG Expands its End-to-End Platform by Submitting Three Patents to the European Patent Office

Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the submission of three patents to the European Patent Office. This underscores Medigene’s commitment to advancing T cell-based immunotherapies for the treatment of solid tumors.

Interferon-Gamma (IFNγ) Biosensor

The first patent submission covers the Company's innovative Interferon-gamma (IFNγ) Biosensor, a technology that enables real-time monitoring and quantification of IFNγ release from cytokine-secreting cells. The proprietary technology allows to better understand immune response dynamics by utilizing a simplified and efficient cytometry detection method. The IFNγ Biosensor technology overcomes the limitations of currently available commercial tools, which are often costly, time-consuming, and prone to errors due to complex procedures that diminish reproducibility. Additionally, conventional methods typically only allow for endpoint measurements and do not support real-time monitoring of IFNγ over extended periods which is made possible through use of this IFNγ Biosensor.

High Precision TCR Tracking (UniTope & TraCR)

Additionally, Medigene has filed two patents for its novel T cell receptor (TCR)-specific Antigen-Antibody combination technology, UniTope & TraCR. This technology incorporates a pair of tools designed to uniquely tag the TCR and exactly track its location. This in turn allows precise evaluation of proliferation, persistence, and localization of a TCR-guided cell therapy, whether studied in vitro or in vivo, thereby offering critical insights into cell therapy efficacy, and mechanisms.

"The patent applications submitted to the European Patent Office further illustrate our unique scientific and technical approach as we further enhance our End-to-End (E2E) Platform by incorporating new proprietary technologies," stated Selwyn Ho, CEO at Medigene. “These innovative tools enable Medigene to increase the overall efficiency for the development of potential best-in-class TCRs and TCR-based therapies. They increase reproducibility in measuring parameters of safety and efficacy from early in the development process onwards, significantly reducing time and cost."

Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions. The Company maintains over 20 different patent families worldwide covering applications protecting Medigene’s 3S (sensitive, specific and safe) TCRs as well as its exclusive E2E Platform technologies.